Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report issued on Wednesday,Benzinga reports. D. Boral Capital currently has a $12.00 price ...
Hosted on MSN1mon
Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation
Quince Therapeutics Background Information ... financial advisors, and small hedge funds. Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment ...